Advanced Solid TumorsPhase 1NCT05731752
Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors
A Phase 1 study testing HX009 in people with Advanced Solid Tumors, run by Hangzhou Hanx Biopharmaceuticals, Ltd. at 1 site in China.
Trial summary
This is an open, multiple-dose administration dose exploratory clinical phase I study to evaluate the safety, tolerability, and PK profile of HX009 Injection in patients with advanced solid tumors and to provide a preliminary measure of its antitumor efficacy. It includes Phase Ia and Phase Ib. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Advanced Solid Tumors
- What is being tested?
- HX009
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteChina
- Study dates
- 28 May 2020to 30 Dec 2024
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- In Phase Ia.
- Subjects must meet all of the following enrollment criteria to be enrolled in this study:
- Voluntarily sign an informed consent form, understand the study and be willing to follow and be capable of completing all trial procedures;
- Male or female, age 18-70 years (including borderline values);
- ECOG score: 0 to 1;
- Advanced malignant solid tumors diagnosed by cytology or histopathology and after failure of standard treatment (disease progression or intolerable) or in the absence of effective therapies;
Show all 25Show fewer
- Subjects must have at least one extracranial lesion for efficacy assessment according to the Solid Tumor Evaluation Criteria (RECIST 1.1), including both measurable and non-measurable lesions. The number of subject cases with all non-measurable lesions must not exceed 1/3 of the total enrollment;
- Expected survival ≥ 12 weeks;
- If prior antitumor therapy has been received, the following are required:
- ≥ 3 weeks between systemic radiation therapy and the first dose, and ≥ 2 weeks between localized radiation therapy or radiation therapy for bone metastases;
- Prior chemotherapy, immunotherapy (PD-1 antibody, PD-L1 antibody, or CTLA-4 antibody, etc.), biologic therapy (tumor vaccine, cytokine, or growth factor for cancer control), and targeted therapy ≥ 4 weeks from the first administration interval (small molecule targeted agent therapy ≥ 2 weeks from the first administration interval);
- Prior immunotherapy with PD-1 antibody, PD-L1 antibody, or CTLA-4 antibody without permanent discontinuation due to prior immunotherapy;
- Prior treatment with a significant anti-tumor herbal or proprietary Chinese medicine ≥ 2 weeks from the first dose;
- In the case of patients with asymptomatic Central Nervous System (CNS) metastases or treated asymptomatic brain metastases, be free of disease progression by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI), be stable for at least 4 weeks, and not require steroid medication;
- Have appropriate organ and hematopoietic function and no severe cardiac, pulmonary, hepatic, or renal dysfunction or immunodeficiency based on the following laboratory tests
- in phase Ib
- Subjects must meet all of the following enrollment criteria to be enrolled in this trial:
- Voluntarily sign an informed consent form, understand the study and be willing to follow and be capable of completing all trial procedures;
- Male or female, age 18-75 years (including borderline values);
- ECOG score: 0 to 1;
- Unresectable/metastatic advanced melanoma diagnosed by cytology or histopathology;
- Cohort A: No prior systemic therapy for advanced melanoma (prior neoadjuvant and adjuvant therapy with last dose completed before 6 months can be enrolled). Cohort A: No prior systemic therapy for advanced melanoma (previous neoadjuvant and adjuvant therapy, completed before 6 months of last dose) Cohort B: Disease progression after treatment with immune checkpoint inhibitors ;
- Subjects must have at least one measurable lesion according to the Solid Tumor Evaluation Criteria (RECIST 1.1);
- Expected survival ≥ 12 weeks;
- have adequate organ and hematopoietic function, and have laboratory results that meet the requirements
Who cannot join
- in Phase Ia:
- Subjects with any of the following are not eligible for enrollment in this study:
- Those who have developed another malignancy within 5 years prior to enrollment, with the exception of cured carcinoma in situ of the cervix and cured basal cell carcinoma of the skin;
- Failure to recover from adverse effects of prior therapy to a CTCAE 5.0 grade score of ≤ grade 1, except for residual alopecia areata effects;
- Subjects with active, or history of, autoimmune disease with potential for relapse (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis, etc.), or at high risk (e.g., have received an organ transplant requiring immunosuppressive therapy). However, subjects with the following diseases are allowed to enroll:
- Type 1 diabetes mellitus that has stabilized with the use of fixed-dose insulin;
Show all 29Show fewer
- Autoimmune hypothyroidism requiring only hormone replacement therapy;
- Skin disorders that do not require systemic therapy (e.g., eczema, rashes covering less than 10% of the body surface, psoriasis without ophthalmologic symptoms, etc.); 4) Anticipated major surgery during this study including the 28-day screening period; 5) Subjects requiring treatment with systemic corticosteroids (dose equivalent to >10 mg prednisone/day) or other immunosuppressive medications within 14 days prior to the first dose or during the study period; enrollment is permitted in the following cases:
- Subjects are permitted to use topical topical or inhaled glucocorticoids;
- Short-term (≤ 7 days) use of glucocorticoids for prophylaxis or treatment of non-autoimmune allergic diseases is permitted; 6) Currently suffering from sudden lung disease, interstitial lung disease, interstitial pneumonia, pulmonary fibrosis, acute lung disease, radiation pneumonitis; 7) systemic diseases that have not been controlled and stabilized by treatment, such as cardiovascular diseases (unstable angina pectoris or myocardial infarction before 6 months, etc.) diabetes mellitus, hypertension, etc; 8) arterial or venous thrombosis or embolic events such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months prior to the first dose; 9) History of infection with human immunodeficiency virus, or other acquired, congenital immunodeficiency disease, or history of organ transplantation, or stem cell transplantation; 10) a history of tuberculosis, or a history of tuberculosis disease at the time of screening 11) those with active chronic hepatitis B or active hepatitis C Hepatitis B virus carriers, hepatitis B stabilized by drug therapy (DNA titer must not be higher than 500 IU/mL or copy number <1000copies/ml) and patients with cured hepatitis C (negative HCV RNA test) may be enrolled; 12) Those who have had a serious infection within 4 weeks prior to the first dose or who have had an active infection requiring oral or intravenous antibiotic therapy within the previous 2 weeks;
- In phase Ib :
- Phase Ib Exclusion Criteria
- Subjects with any of the following are not eligible for enrollment in this study:
- Histologic or pathologic diagnosis of choroidal malignant melanoma;
- Patients with brain metastases, except those who have been treated and are symptomatically stable. Require ongoing corticosteroids as treatment for CNS disorders, allowing stable doses of anticonvulsant therapy.
- Malignancies other than malignant melanoma that have occurred within 5 years prior to enrollment, with the exception of malignancies with negligible risk of metastasis or death and/or curative treatment (e.g., adequately treated carcinoma in situ of the cervix, basal or squamous cell skin carcinoma, limited prostate cancer, ductal carcinoma in situ, or stage I uterine cancer);
- Uncontrolled pleural effusion, abdominal effusion, or pericardial effusion requiring repeated drainage. Those with indwelling drainage tubes are allowed to be enrolled;
- History of blood transfusion within the last 3 months;
- hemolytic anemia, autoimmune thrombocytopenia, or Evan syndrome within the last 3 months;
- prior allogeneic bone marrow transplantation or solid organ transplantation;
- Failure to recover from adverse effects of prior therapy to a CTCAE 5.0 grade score of ≤ grade 1, excluding alopecia areata;
- Major surgery within 4 weeks prior to the first dose of study drug or expected to undergo major surgery during the study period;
- Patients who have received prior CD47 or SIRpa-targeted therapy;
- have received any live or attenuated vaccine within 28 days prior to the first dose of study drug;
- have received oral or intravenous antibiotics (including antifungals) 2 weeks prior to the first dose of study drug, except for those who require prophylactic anti-infective therapy (to prevent urinary tract infections or exacerbations of chronic obstructive pulmonary disease);
- Subjects requiring treatment with systemic corticosteroids (dose equivalent to >10 mg prednisone/day) or other immunosuppressive medications within 14 days prior to the first dose of study drug or during the study period; enrollment is permitted under the following conditions:
- Use of topical topical or inhaled glucocorticoids;
- Short-term (≤ 7 days) use of glucocorticoids for prophylaxis or treatment of non-autoimmune allergic diseases;
- Corticosteroids for the replacement therapy of adrenal insufficiency;
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Phase I Clinical Trial of Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors
This is an open, multiple-dose administration dose exploratory clinical phase I study to evaluate the safety, tolerability, and PK profile of HX009 Injection in patients with advanced solid tumors and to provide a preliminary measure of its antitumor efficacy. It includes Phase Ia and Phase Ib.
phase Ia is a dose exploratory study to evaluate safety, tolerability, and to determine the MTD and/or RP2D.The sponsor and investigator will adjust the magnitude of the dose escalation and the dosing cycle based on the safety and tolerability of HX009 Injection and the PK data that have been obtained, as well as decide whether to add an unplanned dose or dosing cycle to the trial, and recommend the RP2D.The Ia phase dose escalation design model is shown below. The planned dosing cycle for this study is once every 2 weeks (14 days) (Q2W) with IV HX009.
Based on the result of phase 1a,10 mg/kg Q2W was the recommended dose for phase 1b. The aimed population for 1b is patients diagnosed with advanced melanoma, and divided into two cohorts:: cohort A ,untreated patients with unresectable or metastatic advanced melanoma;and Cohort B, patients with unresectable or metastatic malignant melanoma that had been treated with immune checkpoint inhibitor therapy. The enrollment of Cohort B will start first.,and whether the cohort A will be initiated depends on the results of the cohort B .The up to 80 patients will be enrolled in Phase Ib.
Read the detailed description
The study is divided into a screening, treatment, and follow-up period. The Treatment Period may continue to be administered until the investigator determines that the subject no longer benefits, or the subject develops intolerable toxicity, or the subject withdraws informed consent, or the disease progresses or is treated with an antineoplastic agent other than those specified in the protocol, or the subject dies, or is lost to follow-up, or a Phase Ib subject has been administered for 2 years (whichever occurs earliest).
Subjects who withdraw from the study/terminate treatment for any reason are required to return for 1 follow-up visit after the last dose, to collect as many RO blood samples as possible after discontinuation (only partial subjects in Phase Ib), and to collect clinical data on safety as well as survival. During the subsequent follow-up period (for Phase Ib only), subjects or family members will receive a telephone visit to inquire about survival and antitumor therapy.
- Conditions
- Advanced Solid Tumors
- Being tested
- HX009
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HX009Drug
Also called Recombinant humanized anti-CD47/PD-1 bifunctional antibody
The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts
| Study group | Role | What they receive |
|---|---|---|
| HX009 | Experimental | Study treatment: HX009 administered every 2 weeks (14 [±3] days) via intravenous infusion. Receives: Drug: HX009 |
What is being measured
The primary outcome is the main question the study is designed to answer.
In phase Ia: Incidence of Dose Limiting Toxicities (DLT) of HX009 in patients with advanced solid tumors
Adverse events (AEs) determined by the investigator are recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0).
Measured: At the end of Cycle 2 (each cycle is 14 days)
Incidence of adverse events (AE) of HX009 in patients with advanced solid tumors
Adverse events (AEs) determined by the investigator are recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0).
Measured: Collected adverse events from signing of informed consent through at least 28 days after the end of treatment, or until other cancer treatment regimens have been started (whichever occurs earlier).
In phase IB:Incidence of Dose Limiting Toxicities (DLT) in HX009 in patients with advanced solid tumors
Incidence and severity of adverse events as assessed by the investigator according to RECIST 1.1;
Measured: At the end of Cycle 2 (each cycle is 14 days)
Secondary outcomes (13)
In Phase Ia: Pharmacokinetics (PK): Maximum plasma concentration of drug (Cmax)
Highest concentration of drug measured in the PK samples
Measured: At Cycle 1 ,Cycle 6 and Cycles 2 -5 (each cycle is 14 days)
Pharmacokinetics (PK): Time to reach Cmax (Tmax)
Time from dosing until collection of the PK samples with the highest drug concentration.
Measured: At Cycle 1 ,Cycle 6 and Cycles 2 -5(each cycle is 14 days)
Terminal Half-life （t½）of HX009
Terminal phase elimination half-life
Measured: At Cycle 1 ,Cycle 6 and Cycles 2 -5 (each cycle is 14 days)
Area Under the Serum Concentration-time Curve (AUC)
The area under the serum concentration-time curve .
Measured: At Cycle 1 ,Cycle 6 and Cycles 2 -5 (each cycle is 14 days)
Number of Participants With Positive Anti-Drug Antibody (ADA) of HX009
ADA blood samples were assayed for anti-HX009 antibodies.
Measured: At Cycles 1-6, 9, 13, 17, and then every 8 cycles up to approximately 1 years: within 1 hour before infusion (each cycle is 14 days).
Objective response rate (ORR) of HX009 in patients with solid tumors
The ORR is defined as the percentage of participants in the analysis population who had a confirmed Complete Response or Partial Response.
Measured: Approximately 1 years
Duration of response (DoR) of HX009 in patients with solid tumors
The DoR is defined as the time from the first recorded response (CR or PR) to the first recorded tumor progression or death due to any cause.
Measured: Approximately 1 years
Progression-free survival (PFS) of patients with solid tumors treated with HX009
The PFS is defined as the time from the start of the first dose to the first documented disease progression or death of any cause.
Measured: Approximately 1 years
In Phase Ib: ORR
objective response rate assessed by the investigator according to RECIST1.1/iRECIST;
Measured: Approximately 2 years
In Phase Ib: DCR
disease control rate assessed by the investigator according to RECIST1.1/iRECIST;
Measured: Approximately 2 years
In Phase Ib: PFS
progress-freee survival assessed by the investigator according to RECIST1.1/iRECIST;
Measured: Approximately 2 years
In Phase Ib: Cmax
Highest concentration of drug measured in the PK samples
Measured: Approximately 1 years
In phase Ib：AUC
Area Under the Serum Concentration-time Curve (AUC)
Measured: Approximately 1 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Feb 2023
- Study start28 May 2020
- Primary completion30 Dec 2024 (estimated)
- Study completion30 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Solid TumorsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05731752
- Sponsor's protocol ID
- HX009-I-01(CN)
- Status last verified
- Jul 2024
- First submitted
- 29 Jan 2023
- Last updated
- 22 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase I Clinical Trial of Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors
- ClinicalTrials.gov ID
- NCT05731752
- Acronym / sponsor ID
- HX009-I-01(CN)
- Conditions
- Advanced Solid Tumors
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.Industry (pharma, biotech, devices)
- Study start
- 28 May 2020 (actual)
- Primary completion
- 30 Dec 2024 (estimated)
- Study completion
- 30 Dec 2024 (estimated)
- First posted
- 16 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an open, multiple-dose administration dose exploratory clinical phase I study to evaluate the safety, tolerability, and PK profile of HX009 Injection in patients with advanced solid tumors and to provide a preliminary measure of its antitumor efficacy. It includes Phase Ia and Phase Ib.
phase Ia is a dose exploratory study to evaluate safety, tolerability, and to determine the MTD and/or RP2D.The sponsor and investigator will adjust the magnitude of the dose escalation and the dosing cycle based on the safety and tolerability of HX009 Injection and the PK data that have been obtained, as well as decide whether to add an unplanned dose or dosing cycle to the trial, and recommend the RP2D.The Ia phase dose escalation design model is shown below. The planned dosing cycle for this study is once every 2 weeks (14 days) (Q2W) with IV HX009.
Based on the result of phase 1a,10 mg/kg Q2W was the recommended dose for phase 1b. The aimed population for 1b is patients diagnosed with advanced melanoma, and divided into two cohorts:: cohort A ,untreated patients with unresectable or metastatic advanced melanoma;and Cohort B, patients with unresectable or metastatic malignant melanoma that had been treated with immune checkpoint inhibitor therapy. The enrollment of Cohort B will start first.,and whether the cohort A will be initiated depends on the results of the cohort B .The up to 80 patients will be enrolled in Phase Ib.
Detailed description
The study is divided into a screening, treatment, and follow-up period. The Treatment Period may continue to be administered until the investigator determines that the subject no longer benefits, or the subject develops intolerable toxicity, or the subject withdraws informed consent, or the disease progresses or is treated with an antineoplastic agent other than those specified in the protocol, or the subject dies, or is lost to follow-up, or a Phase Ib subject has been administered for 2 years (whichever occurs earliest).
Subjects who withdraw from the study/terminate treatment for any reason are required to return for 1 follow-up visit after the last dose, to collect as many RO blood samples as possible after discontinuation (only partial subjects in Phase Ib), and to collect clinical data on safety as well as survival. During the subsequent follow-up period (for Phase Ib only), subjects or family members will receive a telephone visit to inquire about survival and antitumor therapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| HX009 | Experimental | Drug: HX009Study treatment: HX009 administered every 2 weeks (14 [±3] days) via intravenous infusion. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (25 listed)
- In Phase Ia.
- Voluntarily sign an informed consent form, understand the study and be willing to follow and be capable of completing all trial procedures;
- Male or female, age 18-70 years (including borderline values);
- ECOG score: 0 to 1;
- Advanced malignant solid tumors diagnosed by cytology or histopathology and after failure of standard treatment (disease progression or intolerable) or in the absence of effective therapies;
Key exclusion criteria (29 listed)
- Subjects with any of the following are not eligible for enrollment in this study:
- Type 1 diabetes mellitus that has stabilized with the use of fixed-dose insulin;
- Autoimmune hypothyroidism requiring only hormone replacement therapy;
- Skin disorders that do not require systemic therapy (e.g., eczema, rashes covering less than 10% of the body surface, psoriasis without ophthalmologic symptoms, etc.); 4) Anticipated major surgery during this study including the 28-day screening period; 5) Subjects requiring treatment with systemic corticosteroids (dose equivalent to >10 mg prednisone/day) or other immunosuppressive medications within 14 days prior to the first dose or during the study period; enrollment is permitted in the following cases:
- Subjects are permitted to use topical topical or inhaled glucocorticoids;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HX009Also: Recombinant humanized anti-CD47/PD-1 bifunctional antibodyThe subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts | Drug | HX009 |
Primary outcome
In phase Ia: Incidence of Dose Limiting Toxicities (DLT) of HX009 in patients with advanced solid tumors
Time frame: At the end of Cycle 2 (each cycle is 14 days)
Adverse events (AEs) determined by the investigator are recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0).
Incidence of adverse events (AE) of HX009 in patients with advanced solid tumors
Time frame: Collected adverse events from signing of informed consent through at least 28 days after the end of treatment, or until other cancer treatment regimens have been started (whichever occurs earlier).
Adverse events (AEs) determined by the investigator are recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0).
In phase IB:Incidence of Dose Limiting Toxicities (DLT) in HX009 in patients with advanced solid tumors
Time frame: At the end of Cycle 2 (each cycle is 14 days)
Incidence and severity of adverse events as assessed by the investigator according to RECIST 1.1;
13 secondary outcomes
In Phase Ia: Pharmacokinetics (PK): Maximum plasma concentration of drug (Cmax)
Time frame: At Cycle 1 ,Cycle 6 and Cycles 2 -5 (each cycle is 14 days)
Pharmacokinetics (PK): Time to reach Cmax (Tmax)
Time frame: At Cycle 1 ,Cycle 6 and Cycles 2 -5(each cycle is 14 days)
Terminal Half-life （t½）of HX009
Time frame: At Cycle 1 ,Cycle 6 and Cycles 2 -5 (each cycle is 14 days)
Area Under the Serum Concentration-time Curve (AUC)
Time frame: At Cycle 1 ,Cycle 6 and Cycles 2 -5 (each cycle is 14 days)
Number of Participants With Positive Anti-Drug Antibody (ADA) of HX009
Time frame: At Cycles 1-6, 9, 13, 17, and then every 8 cycles up to approximately 1 years: within 1 hour before infusion (each cycle is 14 days).
Objective response rate (ORR) of HX009 in patients with solid tumors
Time frame: Approximately 1 years
Duration of response (DoR) of HX009 in patients with solid tumors
Time frame: Approximately 1 years
Progression-free survival (PFS) of patients with solid tumors treated with HX009
Time frame: Approximately 1 years
In Phase Ib: ORR
Time frame: Approximately 2 years
In Phase Ib: DCR
Time frame: Approximately 2 years
In Phase Ib: PFS
Time frame: Approximately 2 years
In Phase Ib: Cmax
Time frame: Approximately 1 years
In phase Ib：AUC
Time frame: Approximately 1 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2024.
- Individual participant dataSharing planned: No
Related trials for Advanced Solid Tumors
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
RecruitingPhase 1/2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing HX009 in people with Advanced Solid Tumors, run by Hangzhou Hanx Biopharmaceuticals, Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 25 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
In phase Ia: Incidence of Dose Limiting Toxicities (DLT) of HX009 in patients with advanced solid tumors (time frame: At the end of Cycle 2 (each cycle is 14 days)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2024.